Pfizer’s transition from pandemic reliance to growth in oncology and rare diseases reflects a strategic pivot, supported by recent acquisitions, despite the challenge of rising debt ...

Lawyers for Pfizer and BioNTech claimed that the 'technical contribution' needed was not 'plausibly disclosed' in the patents. At a trial in July, their lawyers told the High Court in London that ...

Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care ...

Pfizer faced more than $2 billion in legal settlement payments over marketing practices for drugs, and around the same time announced it would close a large number of manufacturing and R&D sites ...

Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said ... Agency said in an agenda of the meeting posted on its website. The U.S. Food and Drug Administration (FDA) granted an ...

President Cyril Ramaphosa has welcomed today’s announcement of a collaboration between South Africa’s Biovac Institute and the global pharmaceutical producer Pfizer as a breakthrough in the protection ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

Activist investor Starboard has taken a $1 billion stake in Pfizer, according to a report, Super Micro stock surges, and ...

Pfizer (NYSE:PFE) has voluntarily withdrawn all lots of its sickle cell disease drug Oxbryta, also known as voxelotor, over safety concerns. The pharmaceutical giant said Oxbryta will be withdrawn ...

Pfizer PFE3.46%increase; green up pointing triangle said it is voluntarily withdrawing all lots of its sickle-cell drug Oxbryta in all markets where it is approved, two years after acquiring its ...